Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,739 total articles
Axe Compute Inc., a NASDAQ-listed AI infrastructure platform, announced the launch of its Strategic Compute Reserve (SCR) Dashboard. The dashboard consolidates detailed, real-time insights into the company's GPU asset reserves and stock metrics, improving transparency by integrating the equity valuation with the value and unlock schedule of its AI …
Calidi Biotherapeutics presented new compelling data demonstrating the effectiveness of its RedTail virotherapy platform, which systemically delivers targeted genetic medicines for cancer treatment. The company highlighted its lead candidate CLD-401 and introduced CLD-501 targeting TROP2, aiming to improve T-cell engagers' efficacy in solid tumors …
Enlight Renewable Energy will report its first quarter 2026 financial results on May 5, 2026, ahead of the market open. The company, which operates in solar, wind, and energy storage sectors across the US, Israel, and Europe, will host a conference call and webcast to discuss its results and business outlook.
Kyverna Therapeutics reported positive longer-term follow-up data from the Phase 2 portion of its KYSA-6 trial evaluating mivocabtagene autoleucel (miv-cel), a CAR T therapy, in patients with generalized myasthenia gravis (gMG). The data demonstrate rapid, robust, and sustained clinical improvements through 52 weeks after a single dose, with all pa…
BioCardia announced a favorable outcome from its clinical consultation with Japan's PMDA for CardiAMP Cell Therapy, signaling likely sufficiency of its clinical data to support regulatory approval for ischemic heart failure treatment in Japan. The company is positioned to become the first to offer a minimally invasive biologic therapy for this cond…
Cycurion, Inc. CEO Kevin Kelly discusses the company's strategic transition towards profitable growth through improved operational execution, cost-saving initiatives, and multi-year contract wins, including a significant government partnership. The company aims to grow revenues substantially in the coming years, overcoming prior challenges related …
Artelo Biosciences announces publication of peer-reviewed research demonstrating the analgesic potential of its FABP5 inhibitor ART26.12 across multiple pain models, highlighting a differentiated mechanism with a favorable safety profile from Phase 1 studies. The company plans to initiate multiple ascending dose trials later this year to advance cl…
RedCloud Holdings plc is progressing its RAID AI engine from research to live integration within Turkey's leading distribution network, marking a major step towards commercial deployment. This move follows joint ventures in Turkey and Saudi Arabia, collectively valued up to $80 million, reflecting expansion in high-growth FMCG markets amid global s…
Psyence Biomedical Ltd. (Nasdaq: PBM), a clinical-stage biopharmaceutical company, announces its strategic position as the world's only licensed supplier of pharmaceutical-grade ibogaine sourced directly from Africa. Through its investment in PsyLabs, Psyence has developed a vertically integrated, GMP-compliant platform encompassing sourcing, extra…
NewcelX Ltd. announced an updated corporate presentation emphasizing its strategic collaboration with Eledon Pharmaceuticals to develop a combined cell therapy and immune-protection approach targeting Type 1 Diabetes. The company's flagship program, NCEL-101, integrates stem-cell-derived islet replacement with Eledon's immune-modulation antibody te…
Nexera Technologies Ltd announced that its wholly-owned subsidiary, KeepZone AI Inc., has entered a white label agreement to develop and commercialize an advanced AI-powered real-time voice communication decision support system. This platform aims to enhance operational capabilities in managing multiple voice and radio communication channels simult…
Swvl Holdings Corp announced fiscal year 2025 financial results showing a 41% increase in revenue to $24.2 million and a net income of $1.3 million, marking a return to profitability after a $10.3 million loss in 2024. Revenue growth was driven by significant expansion in the Gulf Cooperation Council (GCC) region, with GCC revenues up 122%, alongsi…
WW International, Inc. announced the appointment of Heather Thiltgen, an experienced healthcare executive with expertise in expanding access to GLP-1 therapies and managing complex healthcare markets, to its Board of Directors. This strategic move aims to support the company’s long-term strategy in evolving its integrated weight health offerings am…
Alpha Compute Corp. (NASDAQ: ALP), formerly AlphaTON Capital Corp., has rebranded to reflect its growing specialization in AI GPU-as-a-service and confidential computing infrastructure that caters to privacy-sensitive enterprise workloads. The company leverages NVIDIA Blackwell-generation GPUs to offer sovereign, encrypted AI compute solutions addr…
Biogen Inc. has entered into an agreement to acquire exclusive rights to develop and commercialize felzartamab in the Greater China region from TJ Biopharma. This acquisition consolidates global rights for felzartamab, a promising CD38-directed antibody in Phase 3 trials for multiple immune-related diseases. Biogen will make a $100 million upfront …
Palvella Therapeutics announced that results from its Phase 3 SELVA and Phase 2 TOIVA clinical trials evaluating QTORIN™ 3.9% rapamycin anhydrous gel will be presented at the ISSVA World Congress 2026. These studies demonstrated statistically significant and clinically meaningful improvements in treating microcystic lymphatic malformations and cuta…
BriaCell Therapeutics presented positive Phase 3 clinical data demonstrating preserved quality of life in heavily pretreated metastatic breast cancer patients receiving Bria-IMT combined with immune checkpoint inhibitors, alongside promising Phase 2 biomarker analyses at the 2026 AACR Annual Meeting. These findings support BriaCell's immunotherapy …
Dragonfly Energy announced a material purchase order valued at over $3 million from Stevens Transport for deployment across nearly 500 trucks throughout 2026. This order encompasses Dragonfly's full heavy-duty trucking product portfolio, including lithium-based solutions aimed at reducing engine idling, improving driver comfort, and lowering total …
New Found Gold Corp. announced a $205 million financing package consisting of a $100 million bought deal equity offering and a $105 million senior secured credit facility with EdgePoint. The funds will finance the initial capital expenditures for the Queensway Gold Project-Phase I, advancing it toward production, as well as general corporate purpos…
Clearmind Medicine Inc., a clinical-stage biotech focused on non-hallucinogenic psychedelic therapeutics, announced positive top-line safety data from its ongoing FDA-approved Phase I/IIa trial of CMND-100, a MEAI-based oral drug candidate targeting Alcohol Use Disorder (AUD). The drug met the primary safety and tolerability endpoint, showing a hig…
Gilat Satellite Networks Ltd., a leader in satellite networking technology, announced it will release its first quarter 2026 financial results on May 13, 2026. The company will host conference calls and webcasts in English and Hebrew to discuss the results and business achievements. Gilat's portfolio includes advanced satellite communication soluti…
Invivyd, Inc.'s Chairman Marc Elia is a featured speaker at the POLITICO Health Care Summit, discussing the future of viral disease prevention with emphasis on monoclonal antibodies as a next-generation approach beyond vaccines. Invivyd recently received FDA emergency use authorization for a monoclonal antibody treatment, underscoring its role in a…
Pasithea Therapeutics announced that the FDA has granted Rare Pediatric Disease Designation (RPDD) to its drug candidate PAS-004 for the treatment of Neurofibromatosis Type 1 (NF1). This designation supports the drug's potential to address this serious pediatric condition affecting approximately 115,000 individuals in the U.S. PAS-004 already holds…
Radiopharm Theranostics announced encouraging initial findings from the Phase 0/1 HEAT clinical trial evaluating 177Lu-RAD202, a first-in-class HER2-targeted radiopharmaceutical, showing meaningful tumor uptake and a favorable safety profile at the lowest 30 mCi dose. The Data Safety and Monitoring Committee has approved advancing to a higher 130 m…
U.S. Energy Corp. announced the closing of an expanded $20 million senior secured debt facility, together with proceeds from a recent equity offering, expected to complete the Phase 1 capital stack for its Big Sky Carbon Hub. The funding provides financial visibility for Phase 1 construction with commercial operations targeted for Q1 2027. The comp…
